REGULATORY

Govt to Hear Opinions from Trade, Professional Groups on Generic Promotion

May 12, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A working group of the government’s administrative reform panel will begin hearings with industry and professional organizations from mid-May in order to consider further steps to ramp up the use of generics in Japan. The hearings will be held once…

To read the full story

Set Earlier-than-FY2020 Date for 80% Generic Target: Govt Working Group
June 19, 2015
Govt Working Group Calls for Switching Contract Manufacturing of Long-Listed Drugs to Generic Production
June 16, 2015
Generic Drug Use May Reach 60% Target Ahead of Schedule, but Raising Target to 80% Would Be “Difficult”: Director Jo of EAD
May 18, 2015

REGULATORY

MHLW Issues Q&A on Conditional Approval System
May 1, 2026
Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…